BMS has two billion-dollar transactions in two days to introduce new drugs and expand AI-assisted new drug R&D cooperation

• On March 2, Iktos and Pfizer reached an AI new drug development cooperation;

• On March 25, Jingtai Technology, an AI drug research and development company driven by digitization and intelligence, and Qingyu Pharmaceutical, a company focused on pioneering drug research and development, reached a strategic cooperation to carry out drug research and development cooperation on multiple anti-tumor drug targets;

• On April 12, NVIDIA and Schrödinger reached a strategic cooperation.
Schrödinger will use the NVIDIA DGX A100™ system to further expand the speed and accuracy of its computational drug discovery platform;

• On April 16, Relay, a precision drug company that combines leading computing and experimental technologies to change the drug discovery process, announced the acquisition of ZebiAI.
ZebiAI is a machine learning (ML-DEL) that applies a large number of experimental DNA coding library data sets to drug discovery.
) Pioneer;

• On April 27th, InveniAI® LLC, which applied advanced AI and machine learning in the field of drug discovery and development to achieve an innovative transformation, announced a multi-target drug discovery collaboration with Shiono Yoshi Pharmaceutical;

• On May 12, Hebo Medicine and Baitu Biopharmaceutical reached a strategic cooperation agreement.
The cooperation will be based on Hebo Biopharma’s fully human genetically modified mouse platform, combined with Baitu Biopharma’s advantages in the field of artificial intelligence, according to The structure and biological characteristics of potential therapeutic targets, and the specific design of antibody drugs with advantageous physical and chemical properties and druggability
.